American Journal of Clinical Dermatology

, Volume 3, Issue 8, pp 557–570 | Cite as

Vaccination Against Cutaneous Leishmaniasis

Current Status
  • Peter C. Melby
Review Article


The different cutaneous leishmaniases are distinct in their etiology, epidemiology, transmission, and geographical distribution. In most instances cutaneous leishmaniasis is limited to one or a few skin ulcers that develop at the site where the parasites were deposited during the bite of the sandfly vector. Lesions typically heal spontaneously after several months but some lesions can be large and follow a chronic, more severe course.

Protective immunity is usually acquired following cutaneous infection with Leishmania spp., so prevention of disease through prophylactic immunization appears to be feasible. Since vaccination with live, virulent parasites is associated with an unacceptable rate of adverse events, attention has turned to the use of killed or attenuated parasite vaccines and defined subunit vaccines. Whole parasite vaccines have the advantage of delivering multiple antigenic epitopes that may be necessary for initiation of a broad-based immune response. Persistent or repeated immune-stimulation by parasite antigens and/or sustained expression of interleukin-12 appear to be critical elements in the development of durable immunity.

A number of purified or recombinant antigens, when co-administered with a vaccine adjuvant, appear promising as vaccine candidates against cutaneous leishmaniasis. The sustained expression of recombinant Leishmania antigens by vaccination with DNA is an attractive approach because it mimics the persistent antigenic stimulation of subclinical infection. Effective vaccine-induced immunity must generate an antigen-specific memory T cell population that, upon exposure to the infecting parasite, rapidly produces a type 1 effector T cell response that leads to interferon-γ-mediated activation of infected macrophages to kill the intracellular parasites. This parasite-directed recall response must be prompt and of sufficient magnitude to overcome the subversive effect that the intracellular infection has on macrophage effector function. It is unlikely that vaccination against cutaneous leishmaniasis would induce sterile immunity, but a small number of parasites are likely to persist subclinically.


Visceral Leishmaniasis Cutaneous Leishmaniasis Virulent Parasite Parasite Challenge Metacyclic Promastigotes 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



This work was supported by a Merit Review Grant from the US Department of Veterans Affairs, and by funding from the National Institutes of Health (AI 48823). The author has no conflicts of interest that are directly relevant to the contents of this manuscript. The author thanks Sunil Ahuja, Seema Ahuja, Greg Anstead, and David Sacks for helpful discussions, and Lydia Melby for help with library research.


  1. 1.
    Anonymous. World Health Organization. Leishmaniasis Control home page [online]. Available from URL: [Accessed 2002 Jan 8 ]Google Scholar
  2. 2.
    Weigle K.A., Santrich C., Martinez F., et al. Epidemiology of cutaneous leishmaniasis in Colombia: a longitudinal study of the natural history, prevalence, and incidence of infection and clinical manifestations. J Infect Dis 1993; 168: 699–708PubMedCrossRefGoogle Scholar
  3. 3.
    Weigle K.A., Valderrama L., Arias A.L., et al. Leishmanin skin test standardization and evaluation of safety, dose, storage, longevity of reaction and sensitization. Am J Trop Med Hyg 1991; 44: 260–271PubMedGoogle Scholar
  4. 4.
    Andrade-Narvaez F.J., Simmonds-Diaz E., Rico-Aguilar S., et al. Incidence of localized cutaneous leishmaniasis (chiclero’s ulcer) in Mexico. Trans R Soc Trop Med Hyg 1990; 84: 219–220PubMedCrossRefGoogle Scholar
  5. 5.
    Davies C.R., Llanos-Cuentas E.A., Pyke S.D., et al. Cutaneous leishmaniasis in the Peruvian Andes: an epidemiological study of infection and immunity. Epidemiol Infect 1995; 114: 297–318PubMedCrossRefGoogle Scholar
  6. 6.
    Guirges S.Y. Natural and experimental re-infection of man with Oriental sore. Ann Trop Med Parasitol 1971; 65: 197–205PubMedGoogle Scholar
  7. 7.
    Saravia N.G., Weigle K., Segura I., et al. Recurrent lesions in human Leishmania braziliensis infection: reactivation or reinfection? Lancet 1990; 336: 398–402PubMedCrossRefGoogle Scholar
  8. 8.
    Sokolova A.N. Preventive vaccination with the living parasites of cutaneous leishmaniasis. Trans Turkmen Cutan-Venereol Inst Ashkhabad 1940, 11–44Google Scholar
  9. 9.
    Marzinowsky E.I., Schurenkowa A. Oriental sore and immunity against it. Trans R Soc Trop Med Hyg 1924; 18: 67–69CrossRefGoogle Scholar
  10. 10.
    Moshkovsky C.D. The ‘principle of re-inoculation’ in oriental sore in relation to prophylactic vaccination. Med Parasit Parasitic Dis 1942; 11: 66–75Google Scholar
  11. 11.
    Berberian D.A. Vaccination and immunity against oriental sore. Trans R Soc Trop Med Hyg 1939; 223: 1417–1419Google Scholar
  12. 12.
    Berberian D.A. Cutaneous leishmaniasis (oriental sore): I, time required for development of immunity after vaccination. Arch Dermatol Syph 1944; 49: 433–435CrossRefGoogle Scholar
  13. 13.
    Sagher F., Verbi S., Zuckerman A. Immunity to reinfection following recovery from cutaneous leishmaniasis (oriental sore). J Invest Dermatol 1955; 24: 417–421PubMedGoogle Scholar
  14. 14.
    Senekji H.A., Beattie C.P. Artificial infection and immunization of man with cultures of Leishmania tropica. Trans R Soc Trop Med Hyg 1941; 34: 415–419CrossRefGoogle Scholar
  15. 15.
    Dostrovsky A., Sagher F., Zuckerman A. Isophasic reaction following experimental superinfection of Leishmania tropica. Arch Dermatol Syph 1952; 66: 665–675CrossRefGoogle Scholar
  16. 16.
    Heinzel F.P., Sadick M.D., Holaday B.J., et al. Reciprocal expression of interferon gamma or interleukin 4 during the resolution or progression of murine leishmaniasis: evidence for expansion of distinct helper T cell subsets. J Exp Med 1989; 169: 59–72PubMedCrossRefGoogle Scholar
  17. 17.
    Heinzel F.P., Sadick M.D., Mutha S.S., et al. Production of interferon gamma, interleukin 2, interleukin 4, and interleukin 10 by CD4+ lymphocytes in vivo during healing and progressive murine leishmaniasis. Proc Natl Acad Sci U S A 1991; 88: 7011–7015PubMedCrossRefGoogle Scholar
  18. 18.
    Sadick M.D., Locksley R.M., Tubbs C., et al. Murine cutaneous leishmaniasis: resistance correlates with the capacity to generate interferon-gamma in response to Leishmania antigens in vitro. J Immunol 1986; 136: 655–661PubMedGoogle Scholar
  19. 19.
    Scott P., Natovitz P., Coffman R.L., et al. Immunoregulation of cutaneous leishmaniasis: T cell lines that transfer protective immunity or exacerbation belong to different T helper subsets and respond to distinct parasite antigens. J Exp Med 1988; 168: 1675–1684PubMedCrossRefGoogle Scholar
  20. 20.
    Heinzel F.P., Rerko R.M., Hujer A.M. Underproduction of interleukin-12 in susceptible mice during progressive leishmaniasis is due to decreased CD40 activity. Cell Immunol 1998; 184: 129–142PubMedCrossRefGoogle Scholar
  21. 21.
    Heinzel F.P., Rerko R.M., Ahmed F., et al. Endogenous IL-12 is required for control of Th2 cytokine responses capable of exacerbating leishmaniasis in normally resistant mice. J Immunol 1995; 155: 730–739PubMedGoogle Scholar
  22. 22.
    Carvalho E.M., Johnson W.D., Barreto E., et al. Cell mediated immunity in American cutaneous and mucosal leishmaniasis. J Immunol 1985; 135: 4144–4148PubMedGoogle Scholar
  23. 23.
    Cooper A.M., Melby P.C., Karp C.L., et al. T-cell responses to infected autologous monocytes in patients with cutaneous and mucocutaneous leishmaniasis. Clin Diagn Lab Immunol 1994; 1: 304–309PubMedGoogle Scholar
  24. 24.
    Melby P.C., Neva F.A., Sacks D.L. Profile of human T cell response to leishmanial antigens: analysis by immunoblotting. J Clin Invest 1989; 83: 1868–1875PubMedCrossRefGoogle Scholar
  25. 25.
    Mendonca S.C., Coutinho S.G., Amendoeira R.R., et al. Human american cutaneous leishmaniasis (Leishmania b. braziliensis) in Brazil: lymphoproliferative responses and influence of therapy. Clin Exp Immunol 1986; 64: 269–276PubMedGoogle Scholar
  26. 26.
    Gicheru M.M., Olobo J.O., Anjili C.O., et al. Vervet monkeys vaccinated with killed Leishmania major parasites and interleukin-12 develop a type 1 immune response but are not protected against challenge infection. Infect Immun 2001; 69: 245–251PubMedCrossRefGoogle Scholar
  27. 27.
    Sjolander A., Baldwin T.M., Curtis J.M., et al. Vaccination with recombinant parasite surface antigen 2 from Leishmania major induces a Th1 type of immune response but does not protect against infection. Vaccine 1998; 16: 2077–2084PubMedCrossRefGoogle Scholar
  28. 28.
    Prina E., Lang T., Glaichenhaus N., et al. Presentation of the protective parasite antigen LACK by Leishmania- infected macrophages. J Immunol 1996; 156: 4318–4327PubMedGoogle Scholar
  29. 29.
    Barral-Netto M., Barral A., Brownell C.E., et al. Transforming growth factor-beta in leishmanial infection: a parasite escape mechanism. Science 1992; 257: 545–548PubMedCrossRefGoogle Scholar
  30. 30.
    Pirmez C., Yamamura M., Uyemura K., et al. Cytokine patterns in the pathogenesis of human leishmaniasis. J Clin Invest 1993; 91: 1390–1395PubMedCrossRefGoogle Scholar
  31. 31.
    Melby P.C., Andrade-Narvaez F.J., Darnell B.J., et al. Increased expression of proinflammatory cytokines in chronic lesions of human cutaneous leishmaniasis. Infect Immun 1994; 62: 837–842PubMedGoogle Scholar
  32. 32.
    Caceres-Dittmar G., Tapia F.J., Sanchez M.A., et al. Determination of the cytokine profile in American cutaneous leishmaniasis using the polymerase chain reaction. Clin Exp Immunol 1993; 91: 500–505PubMedCrossRefGoogle Scholar
  33. 33.
    Launois P., Swihart K.G., Milon G., et al. Early production of IL-4 in susceptible mice infected with Leishmania major rapidly induces IL-12 unresponsiveness. J Immunol 1997; 158: 3317–3324PubMedGoogle Scholar
  34. 34.
    Gurunathan S., Sacks D.L., Brown D.R., et al. Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected with Leishmania major. J Exp Med 1997; 186: 1137–1147PubMedCrossRefGoogle Scholar
  35. 35.
    Moll H., Scollay R., Mitchell G.F. Resistance to cutaneous leishmaniasis in nude mice injected with L3T4+ T cells but not with Ly-2+ T cells. Immunol Cell Biol 1988; 66: 57–63PubMedCrossRefGoogle Scholar
  36. 36.
    Muller I., Pedrazzini T., Kropf P., et al. Establishment of resistance to Leishmania major infection in susceptible BALB/c mice requires parasite-specific CD8+ T cells. Int Immunol 1991; 3: 587–597PubMedCrossRefGoogle Scholar
  37. 37.
    Muller I., Kropf P., Etges R.J., et al. Gamma interferon response in secondary Leishmania major infection: role of CD8+ T cells. Infect Immun 1993; 61: 3730–3738PubMedGoogle Scholar
  38. 38.
    Gurunathan S., Stobie L., Prussin C., et al. Requirements for the maintenance of Th1 immunity in vivo following DNA vaccination: a potential immunoregulatory role for CD8+ T cells. J Immunol 2000; 165: 915–924PubMedGoogle Scholar
  39. 39.
    Fruth U., Solioz N., Louis J.A. Leishmania major interferes with antigen presentation by infected macrophages. J Immunol 1993; 150: 1857–1864PubMedGoogle Scholar
  40. 40.
    Nandan D., Reiner N.E. Attenuation of gamma interferon-induced tyrosine phosphorylation in mononuclear phagocytes infected with Leishmania donovani: selective inhibition of signaling through Janus kinases and Stat1. Infect Immun 1995; 63: 4495–4500PubMedGoogle Scholar
  41. 41.
    Reiner N.E., Ng W., Ma T., et al. Kinetics of gamma interferon binding and induction of major histocompatibility complex class II mRNA in Leishmania-infected macrophages. Proc Natl Acad Sci U S A 1988; 85: 4330–4334PubMedCrossRefGoogle Scholar
  42. 42.
    Reiner N.E., Ng W., Wilson C.B., et al. Modulation of in vitro monocyte cytokine responses to Leishmania donovani: interferon-gamma prevents parasite-induced inhibition of interleukin 1 production and primes monocytes to respond to Leishmania by producing both tumor necrosis factor-alpha and interleukin 1. J Clin Invest 1990; 85: 1914–1924PubMedCrossRefGoogle Scholar
  43. 43.
    Reiner N.E., Malemud C.J. Arachidonic acid metabolism by murine peritoneal macrophages infected with Leishmania donovani: in vitro evidence for parasite-induced alterations in cyclooxygenase and lipoxygenase pathways. J Immunol 1985; 134: 556–563PubMedGoogle Scholar
  44. 44.
    Reiner N.E. Parasite accessory cell interactions in murine leishmaniasis: I, evasion and stimulus-dependent suppression of the macrophage interleukin 1 response by Leishmania donovani. J Immunol 1987; 138: 1919–1925PubMedGoogle Scholar
  45. 45.
    Reiner N.E., Ng W., McMaster W.R. Parasite-accessory cell interactions in murine leishmaniasis: II, Leishmania donovani suppresses macrophage expression of class I and class II major histocompatibility complex gene products. J Immunol 1987; 138: 1926–1932PubMedGoogle Scholar
  46. 46.
    Olivier M., Brownsey R.W., Reiner N.E. Defective stimulus-response coupling in human monocytes infected with Leishmania donovani is associated with altered activation and translocation of protein kinase C. Proc Natl Acad Sci U S A 1992; 89: 7481–7485PubMedCrossRefGoogle Scholar
  47. 47.
    Terkeltaub R., Firestein G.S., Kornbluth R.S., et al. The effects of gamma-interferon on human peripheral blood monocyte/macrophage-mediated bone particle degradation. Bone Miner 1990; 8: 131–143PubMedCrossRefGoogle Scholar
  48. 48.
    Firestein G.S., Zvaifler N.J. Down regulation of human monocyte differentiation antigens by interferon gamma. Cell Immunol 1987; 104: 343–354PubMedCrossRefGoogle Scholar
  49. 49.
    Ahmed R., Gray D. Immunological memory and protective immunity: understanding their relation. Science 1996; 272: 54–60PubMedCrossRefGoogle Scholar
  50. 50.
    Kenney R.T., Sacks D.L., Sypek J.P., et al. Protective immunity using recombinant human IL-12 and alum as adjuvants in a primate model of cutaneous leishmaniasis. J Immunol 1999; 163: 4481–4488PubMedGoogle Scholar
  51. 51.
    Stobie L., Gurunathan S., Prussin C., et al. The role of antigen and IL-12 in sustaining Th1 memory cells in vivo: IL-12 is required to maintain memory/effector Th1 cells sufficient to mediate protection to an infectious parasite challenge. Proc Natl Acad Sci U S A 2000; 97: 8427–8432PubMedCrossRefGoogle Scholar
  52. 52.
    Kamhawi S., Belkaid Y., Modi G., et al. Protection against cutaneous leishmaniasis resulting from bites of uninfected sand flies. Science 2000; 290: 1351–1354PubMedCrossRefGoogle Scholar
  53. 53.
    Belkaid Y., Valenzuela J.G., Kamhawi S., et al. Delayed-type hypersensitivity to Phlebotomus papatasi sand fly bite: an adaptive response induced by the fly? Proc Natl Acad Sci U S A 2000; 97: 6704–6709PubMedCrossRefGoogle Scholar
  54. 54.
    Belkaid Y., Kamhawi S., Modi G., et al. Development of a natural model of cutaneous leishmaniasis: powerful effects of vector saliva and saliva preexposure on the long-term outcome of Leishmania major infection in the mouse ear dermis. J Exp Med 1998; 188: 1941–1953PubMedCrossRefGoogle Scholar
  55. 55.
    Titus R.G., Ribeiro J.M. Salivary gland lysates from the sand fly Lutzomyia longipalpis enhance Leishmania infectivity. Science 1988; 239: 1306–1308PubMedCrossRefGoogle Scholar
  56. 56.
    Valenzuela J.G., Belkaid Y., Garfield M.K., et al. Toward a defined anti-Leishmania vaccine targeting vector antigens: characterization of a protective salivary protein. J Exp Med 2001; 194: 331–3342PubMedCrossRefGoogle Scholar
  57. 57.
    Manson-Bahr P.E.C. Active immunization in leishmaniasis. In: Garnham P.C.C., Pierce A.E., Roitt J., editors. Immunity to Protozoa. Oxford: Blackwell Scientific Publications, 1963: 246–252Google Scholar
  58. 58.
    Nicolle M.M.C., Manceaux L. Recherches sur le bouton d’Orient. Annales de l’Institut Pasteur 1910; 24: 673–720Google Scholar
  59. 59.
    Melby P.C. Experimental leishmaniasis in humans: review. Rev Infect Dis 1991; 13: 1009–1017PubMedCrossRefGoogle Scholar
  60. 60.
    Naggan L., Gunders A.E., Michaeli D. Follow-up study of a vaccination programme against cutaneous leishmaniasis: II, vaccination with a recently isolated strain of L. tropica from Jericho. Trans R Soc Trop Med Hyg 1972; 66: 239–243PubMedCrossRefGoogle Scholar
  61. 61.
    Hoare C.A. Cutaneous leishmaniasis: critical review of recent Russian work. Trop Dis Bull 1944; 41: 331–345Google Scholar
  62. 62.
    Katzenellenbogen I. Vaccination against oriental sore: report of results of five hundred and fifty-five inoculations. Arch Dermatol Syph 1944; 50: 239–242CrossRefGoogle Scholar
  63. 63.
    Modabber F. Experiences with vaccines against cutaneous leishmaniasis: of men and mice. Parasitology 1989; 98 Suppl.: S49–S60PubMedCrossRefGoogle Scholar
  64. 64.
    Modabber F. Vaccines against leishmaniasis. Ann Trop Med Parasitol 1995; 89 Suppl. 1: 83–88PubMedGoogle Scholar
  65. 65.
    Handman E., Hocking R.E., Mitchell G.F., et al. Isolation and characterization of infective and non-infective clones of Leishmania tropica. Mol Biochem Parasitol 1983; 7: 111–126PubMedCrossRefGoogle Scholar
  66. 66.
    Mitchell G.F., Handman E., Spithill T.W. Vaccination against cutaneous leishmaniasis in mice using nonpathogenic cloned promastigotes of Leishmania major and importance of route of injection. Aust J Exp Biol Med Sci 1984; 62: 145–153PubMedCrossRefGoogle Scholar
  67. 67.
    Howard J.G., Nicklin S., Hale C., et al. Prophylactic immunization against experimental leishmaniasis: I, protection induced in mice genetically vulnerable to fatal Leishmania tropica infection. J Immunol 1982; 129: 2206–2212PubMedGoogle Scholar
  68. 68.
    Liew F.Y., Howard J.G., Hale C. Prophylactic immunization against experimental leishmaniasis: III, protection against fatal Leishmania tropica infection induced by irradiated promastigotes involves Lyt-1+2- T cells that do not mediate cutaneous DTH. J Immunol 1984; 132: 456–461PubMedGoogle Scholar
  69. 69.
    Howard J.G., Liew F.Y., Hale C., et al. Prophylactic immunization against experimental leishmaniasis: II, further characterization of the protective immunity against fatal Leishmania tropica infection induced by irradiated promastigotes. J Immunol 1984; 132: 450–455PubMedGoogle Scholar
  70. 70.
    Liew F.Y., Hale C., Howard J.G. Prophylactic immunization against experimental leishmaniasis: IV, subcutaneous immunization prevents the induction of protective immunity against fatal Leishmania major infection. J Immunol 1985; 135: 2095–2101PubMedGoogle Scholar
  71. 71.
    Rivier D., Shah R., Bovay P., et al. Vaccine development against cutaneous leishmaniasis: subcutaneous administration of radioattenuated parasites protects CBA mice against virulent Leishmania major challenge. Parasite Immunol 1993; 15: 75–84PubMedCrossRefGoogle Scholar
  72. 72.
    Aebischer T., Morris L., Handman E. Intravenous injection of irradiated Leishmania major into susceptible BALB/c mice: immunization or protective tolerance. Int Immunol 1994; 6: 1535–1543PubMedCrossRefGoogle Scholar
  73. 73.
    Veras P., Brodskyn C., Balestieri F., et al. A dhfr-ts- Leishmania major knockout mutant cross-protects against Leishmania amazonensis. Mem Inst Oswaldo Cruz 1999; 94: 491–496PubMedCrossRefGoogle Scholar
  74. 74.
    Titus R.G., Gueiros-Filho F.J., de Freitas L.A.,et al. Development of a safe live Leishmania vaccine line by gene replacement. Proc Natl Acad Sci U S A 1995; 92: 10267–10271PubMedCrossRefGoogle Scholar
  75. 75.
    Alexander J., Coombs G.H., Mottram J.C. Leishmania mexicana cysteine proteinase-deficient mutants have attenuated virulence for mice and potentiate a Th1 response. J Immunol 1998; 161: 6794–6801PubMedGoogle Scholar
  76. 76.
    Pessoa S.B. Segunda nota sobre a vacinacao preventiva na leishmaniose tegumentar americana com leptomonas mortas. Rev Paul Med 1941; 19: 1–9Google Scholar
  77. 77.
    Pessoa S.B. Profilaxia da leishmaniose tegumentar no Estado de Sao Paulo. Folha Med 1941; 22: 157–161Google Scholar
  78. 78.
    Mayrink W., da Costa C.A., Magalhaes P.A., et al. A field trial of a vaccine against American dermal leishmaniasis. Trans R Soc Trop Med Hyg 1979; 73: 385–387PubMedCrossRefGoogle Scholar
  79. 79.
    Mayrink W., Williams P., da Costa C.A., et al. An experimental vaccine against American dermal leishmaniasis: experience in the State of Espirito Santo, Brazil. Ann Trop Med Parasitol 1985; 79: 259–269PubMedGoogle Scholar
  80. 80.
    Antunes C.M., Mayrink W., Magalhaes P.A., et al. Controlled field trials of a vaccine against New World cutaneous leishmaniasis. Int J Epidemiol 1986; 15: 572–580PubMedCrossRefGoogle Scholar
  81. 81.
    Castes M., Blackwell J., Trujillo D., et al. Immune response in healthy volunteers vaccinated with killed leishmanial promastigotes plus BCG, I: skin-test reactivity, T-cell proliferation and interferon-gamma production. Vaccine 1994; 12: 1041–1051PubMedCrossRefGoogle Scholar
  82. 82.
    Nascimento E., Mayrink W., da Costa C.A., et al. Vaccination of humans against cutaneous leishmaniasis: cellular and humoral immune responses. Infect Immun 1990; 58: 2198–2203PubMedGoogle Scholar
  83. 83.
    Velez I.D., Agudelo S., Arbelaez M.P., et al. Safety and immunogenicity of a killed Leishmania (L.) amazonensis vaccine against cutaneous leishmaniasis in Colombia: a randomized controlled trial. Trans R Soc Trop Med Hyg 2000; 94: 698–703PubMedCrossRefGoogle Scholar
  84. 84.
    Armijos R.X., Weigel M.M., Aviles H., et al. Field trial of a vaccine against New World cutaneous leishmaniasis in an at-risk child population: safety, immunogenicity, and efficacy during the first 12 months of follow-up. J Infect Dis 1998; 177: 1352–1357PubMedCrossRefGoogle Scholar
  85. 85.
    Momeni A.Z., Jalayer T., Emamjomeh M., et al. A randomised, double-blind, controlled trial of a killed L. major vaccine plus BCG against zoonotic cutaneous leishmaniasis in Iran. Vaccine 1999; 17: 466–472PubMedCrossRefGoogle Scholar
  86. 86.
    Sharifi I., FeKri A.R., Aflatonian M.R., et al. Randomised vaccine trial of single dose of killed Leishmania major plus BCG against anthroponotic cutaneous leishmaniasis in Bam, Iran. Lancet 1998; 351: 1540–1543PubMedCrossRefGoogle Scholar
  87. 87.
    Khalil E.A., El Hassan A.M., Zijlstra E.E., et al. Autoclaved Leishmania major vaccine for prevention of visceral leishmaniasis: a randomised, double-blind, BCG-controlled trial in Sudan. Lancet 2000; 356: 1565–1569PubMedCrossRefGoogle Scholar
  88. 88.
    Afonso L.C., Scharton T.M., Vieira L.Q., et al. The adjuvant effect of interleukin-12 in a vaccine against Leishmania major. Science 1994; 263: 235–237PubMedCrossRefGoogle Scholar
  89. 89.
    Mendez S., Gurunathan S., Kamhawi S., et al. The potency and durability of DNA-and protein-based vaccines against Leishmania major evaluated using low-dose, intradermal challenge. J Immunol 2001; 166: 5122–5128PubMedGoogle Scholar
  90. 90.
    Belkaid Y., Mendez S., Lira R., et al. A natural model of Leishmania major infection reveals a prolonged silent phase of parasite amplification in the skin before the onset of lesion formation and immunity. J Immunol 2000; 165: 969–977PubMedGoogle Scholar
  91. 91.
    Russell D.G., Alexander J. Effective immunization against cutaneous leishmaniasis with defined membrane antigens reconstituted into liposomes [published erratum appears in J Immunol 1988 Apr 15; 140 (8): 2858]. J Immunol 1988; 140: 1274–1279PubMedGoogle Scholar
  92. 92.
    Rivier D., Bovay P., Shah R., et al. Vaccination against Leishmania major in a CBA mouse model of infection: role of adjuvants and mechanism of protection. Parasite Immunol 1999; 21: 461–473PubMedCrossRefGoogle Scholar
  93. 93.
    Handman E., Button L.L., McMaster R.W. Leishmania major: production of recombinant gp63, its antigenicity and immunogenicity in mice. Exp Parasitol 1990; 70: 427–435PubMedCrossRefGoogle Scholar
  94. 94.
    Papadopoulou G., Karagouni E., Dotsika E. ISCOMs vaccine against experimental leishmaniasis. Vaccine 1998; 16: 885–892PubMedCrossRefGoogle Scholar
  95. 95.
    Gonzalez C.R., Noriega F.R., Huerta S., et al. Immunogenicity of a salmonella typhi CVD 908 candidate vaccine strain expressing the major surface protein gp63 of Leishmania mexicana mexicana. Vaccine 1998; 16: 1043–1052PubMedCrossRefGoogle Scholar
  96. 96.
    McSorley S.J., Xu D., Liew F.Y. Vaccine efficacy of salmonella strains expressing glycoprotein 63 with different promoters. Infect Immun 1997; 65: 171–178PubMedGoogle Scholar
  97. 97.
    Yang D.M., Fairweather N., Button L.L., et al. Oral Salmonella typhimurium (AroA-) vaccine expressing a major leishmanial surface protein (gp63) preferentially induces T helper 1 cells and protective immunity against leishmaniasis. J Immunol 1990; 145: 2281–2285PubMedGoogle Scholar
  98. 98.
    Xu D., McSorley S.J., Chatfield S.N., et al. Protection against Leishmania major infection in genetically susceptible BALB/c mice by gp63 delivered orally in attenuated Salmonella typhimurium (AroA- AroD-). Immunology 1995; 85: 1–7PubMedGoogle Scholar
  99. 99.
    Abdelhak S., Louzir H., Timm J., et al. Recombinant BCG expressing the Leishmania surface antigen Gp63 induces protective immunity against Leishmania major infection in BALB/c mice. Microbiology 1995; 141: 1585–1592PubMedCrossRefGoogle Scholar
  100. 100.
    Connell N.D., Medina-Acosta E., McMaster W.R., et al. Effective immunization against cutaneous leishmaniasis with recombinant bacille Calmette-Guerin expressing the Leishmania surface proteinase gp63. Proc Natl Acad Sci U S A 1993; 90: 11473–11477PubMedCrossRefGoogle Scholar
  101. 101.
    Olobo J.O., Anjili C.O., Gicheru M.M., et al. Vaccination of vervet monkeys against cutaneous leishmaniosis using recombinant Leishmania major surface glycoprotein’ (gp63). Vet Parasitol 1995; 60: 199–212PubMedCrossRefGoogle Scholar
  102. 102.
    Jardim A., Alexander J., Teh H.S., et al. Immunoprotective Leishmania major synthetic T cell epitopes. J Exp Med 1990; 172: 645–648PubMedCrossRefGoogle Scholar
  103. 103.
    Spitzer N., Jardim A., Lippert D., et al. Long-term protection of mice against Leishmania major with a synthetic peptide vaccine. Vaccine 1999; 17: 1298–1300PubMedCrossRefGoogle Scholar
  104. 104.
    Frankenburg S., Axelrod O., Kutner S., et al. Effective immunization of mice against cutaneous leishmaniasis using an intrinsically adjuvanted synthetic lipopeptide vaccine. Vaccine 1996; 14: 923–929PubMedCrossRefGoogle Scholar
  105. 105.
    Walker P.S., Scharton-Kersten T., Rowton E.D., et al. Genetic immunization with glycoprotein 63 cDNA results in a helper T cell type 1 immune response and protection in a murine model of leishmaniasis. Hum Gene Ther 1998; 9: 1899–1907PubMedCrossRefGoogle Scholar
  106. 106.
    Xu D., Liew F.Y. Protection against leishmaniasis by injection of DNA encoding a major surface glycoprotein, gp63, of L. major. Immunology 1995; 84: 173–176PubMedGoogle Scholar
  107. 107.
    Champsi J., McMahon-Pratt D. Membrane glycoprotein M-2 protects against Leishmania amazonensis infection. Infect Immun 1988; 56: 3272–3279PubMedGoogle Scholar
  108. 108.
    McMahon-Pratt D., Rodriguez D., Rodriguez J.R., et al. Recombinant vaccinia viruses expressing GP46/M-2 protect against Leishmania infection. Infect Immun 1993; 61: 3351–3359PubMedGoogle Scholar
  109. 109.
    Handman E., Symons F.M., Baldwin T.M., et al. Protective vaccination with promastigote surface antigen 2 from Leishmania major is mediated by a TH1 type of immune response. Infect Immun 1995; 63: 4261–4267PubMedGoogle Scholar
  110. 110.
    Sjolander A., Baldwin T.M., Curtis J.M., et al. Induction of a Th1 immune response and simultaneous lack of activation of a Th2 response are required for generation of immunity to leishmaniasis. J Immunol 1998; 160: 3949–3957PubMedGoogle Scholar
  111. 111.
    Mougneau E., Altare F., Wakil A.E., et al. Expression cloning of a protective Leishmania antigen. Science 1995; 268: 563–566PubMedCrossRefGoogle Scholar
  112. 112.
    Gurunathan S., Prussin C., Sacks D.L., et al. Vaccine requirements for sustained cellular immunity to an intracellular parasitic infection. Nat Med 1998; 4: 1409–1415PubMedCrossRefGoogle Scholar
  113. 113.
    Skeiky Y.A., Kennedy M., Kaufman D., et al. LeIF: a recombinant Leishmania protein that induces an IL-12-mediated Th1 cytokine profile. J Immunol 1998; 161: 6171–6179PubMedGoogle Scholar
  114. 114.
    Soong L., Duboise S.M., Kima P., et al. Leishmania pifanoi amastigote antigens protect mice against cutaneous leishmaniasis. Infect Immun 1995; 63: 3559–3566PubMedGoogle Scholar
  115. 115.
    Webb J.R., Campos-Neto A., Ovendale P.J., et al. Human and murine immune responses to a novel Leishmania major recombinant protein encoded by members of a multicopy gene family. Infect Immun 1998; 66: 3279–3289PubMedGoogle Scholar
  116. 116.
    Campos-Neto A., Porrozzi R., Greeson K., et al. Protection against cutaneous leishmaniasis induced by recombinant antigens in murine and nonhuman primate models of the human disease. Infect Immun 2001; 69: 4103–4108PubMedCrossRefGoogle Scholar
  117. 117.
    Rafati S., Baba A.A., Bakhshayesh M., et al. Vaccination of BALB/c mice with Leishmania major amastigote-specific cysteine proteinase. Clin Exp Immunol 2000; 120: 134–138PubMedCrossRefGoogle Scholar
  118. 118.
    Aebischer T., Wolfram M., Patzer S.I., et al. Subunit vaccination of mice against new world cutaneous leishmaniasis: comparison of three proteins expressed in amastigotes and six adjuvants. Infect Immun 2000; 68: 1328–1336PubMedCrossRefGoogle Scholar
  119. 119.
    McConville M.J., Bacic A., Mitchell G.F., et al. Lipophosphoglycan of Leishmania major that vaccinates against cutaneous leishmaniasis contains an alkylglycerophosphoinositol lipid anchor. Proc Natl Acad Sci U S A 1987; 84: 8941–8945PubMedCrossRefGoogle Scholar
  120. 120.
    Handman E., Mitchell G.F. Immunization with Leishmania receptor for macrophages protects mice against cutaneous leishmaniasis. Proc Natl Acad Sci U S A 1985; 82: 5910–5914PubMedCrossRefGoogle Scholar
  121. 121.
    Mendonca S.C., Russell D.G., Coutinho S.G. Analysis of the human T cell responsiveness to purified antigens of Leishmania: lipophosphoglycan (LPG) and glycoprotein 63 (gp 63). Clin Exp Immunol 1991; 83: 472–478PubMedCrossRefGoogle Scholar
  122. 122.
    Jardim A., Tolson D.L., Turco S.J., et al. The Leishmania donovani lipophosphoglycan T lymphocyte-reactive component is a tightly associated protein complex. J Immunol 1991; 147: 3538–3544PubMedGoogle Scholar
  123. 123.
    Russo D.M., Turco S.J., Burns Jr J.M., et al. Stimulation of human T lymphocytes by Leishmania lipophosphoglycan- associated proteins. J Immunol 1992; 148: 202–207PubMedGoogle Scholar
  124. 124.
    Jardim A., Funk V., Caprioli R.M., et al. Isolation and structural characterization of the Leishmania donovani kinetoplastid membrane protein-11, a major immunoreactive membrane glycoprotein. Biochem J 1995; 305: 307–313PubMedGoogle Scholar
  125. 125.
    Russo D.M., Burns Jr J.M., Carvalho E.M., et al. Human T cell responses to gp63, a surface antigen of Leishmania. J Immunol 1991; 147: 3575–3580PubMedGoogle Scholar
  126. 126.
    Julia V., Glaichenhaus N. CD4 (+) T cells which react to the Leishmania major LACK antigen rapidly secrete interleukin-4 and are detrimental to the host in resistant B10D2 mice. Infect Immun 1999; 67: 3641–3644PubMedGoogle Scholar
  127. 127.
    Julia V., Rassoulzadegan M., Glaichenhaus N. Resistance to Leishmania major induced by tolerance to a single antigen. Science 1996; 274: 421–423PubMedCrossRefGoogle Scholar
  128. 128.
    Launois P., Maillard I., Pingel S., et al. IL-4 rapidly produced by V beta 4 V alpha 8 CD4+ T cells instructs Th2 development and susceptibility to Leishmania major in BALB/c mice. Immunity 1997; 6: 541–549PubMedCrossRefGoogle Scholar
  129. 129.
    Scott P., Caspar P., Sher A. Protection against Leishmania major in BALB/c mice by adoptive transfer of a T cell clone recognizing a low molecular weight antigen released by promastigotes. J Immunol 1990; 144: 1075–1079PubMedGoogle Scholar
  130. 130.
    Soussi N., Milon G., Colle J.H., et al. Listeria monocytogenes as a short-lived delivery system for the induction of type 1 cell-mediated immunity against the p36/LACK antigen of Leishmania major. Infect Immun 2000; 68: 1498–1506PubMedCrossRefGoogle Scholar
  131. 131.
    Lohman K.L., Langer P.J., McMahon-Pratt D. Molecular cloning and characterization of the immunologically protective surface glycoprotein GP46/M-2 of Leishmania amazonensis. Proc Natl Acad Sci U S A 1990; 87: 8393–8397PubMedCrossRefGoogle Scholar
  132. 132.
    McMahon-Pratt D., Traub-Cseko Y., Lohman K.L., et al. Loss of the GP46/M-2 surface membrane glycoprotein gene family in the Leishmania braziliensis complex. Mol Biochem Parasitol 1992; 50: 151–160PubMedCrossRefGoogle Scholar
  133. 133.
    Murray P.J., Spithill T.W., Handman E. The PSA-2 glycoprotein complex of Leishmania major is a glycosylphosphatidylinositol-linked promastigote surface antigen. J Immunol 1989; 143: 4221–4226PubMedGoogle Scholar
  134. 134.
    Kima P.E., Ruddle N.H., McMahon-Pratt D. Presentation via the class I pathway by Leishmania amazonensis-infected macrophages of an endogenous leishmanial antigen to CD8+ T cells. J Immunol 1997; 159: 1828–1834PubMedGoogle Scholar
  135. 135.
    Silveira F.T., Blackwell J.M., Ishikawa E.A., et al. T cell responses to crude and defined leishmanial antigens in patients from the lower Amazon region of Brazil infected with different species of Leishmania of the subgenera Leishmania and Viannia. Parasite Immunol 1998; 20: 19–26PubMedGoogle Scholar
  136. 136.
    Kemp M., Handman E., Kemp K., et al. The Leishmania promastigote surface antigen-2 (PSA-2) is specifically recognised by Th1 cells in humans with naturally acquired immunity to L. major. FEMS Immunol Med Microbiol 1998; 20: 209–218PubMedCrossRefGoogle Scholar
  137. 137.
    Webb J.R., Kaufmann D., Campos-Neto A., et al. Molecular cloning of a novel protein antigen of Leishmania major that elicits a potent immune response in experimental murine leishmaniasis. J Immunol 1996; 157: 5034–5041PubMedGoogle Scholar
  138. 138.
    Haberer J.E., Da-Cruz A.M., Soong L., et al. Leishmania pifanoi amastigote antigen P-4: epitopes involved in T-cell responsiveness in human cutaneous leishmaniasis. Infect Immun 1998; 66: 3100–3105PubMedGoogle Scholar
  139. 139.
    Kar S., Soong L., Colmenares M., et al. The immunologically protective P-4 antigen of Leishmania amastigotes: a developmentally regulated single strandspecific nuclease associated with the endoplasmic reticulum. J Biol Chem 2000; 275: 37789–37797PubMedCrossRefGoogle Scholar
  140. 140.
    Skeiky Y.A., Guderian J.A., Benson D.R., et al. A recombinant Leishmania antigen that stimulates human peripheral blood mononuclear cells to express a Th1-type cytokine profile and to produce interleukin 12. J Exp Med 1995; 181: 1527–1537PubMedCrossRefGoogle Scholar
  141. 141.
    Probst P., Skeiky Y.A., Steeves M., et al. A Leishmania protein that modulates interleukin (IL)-12, IL-10 and tumor necrosis factor-alpha production and expression of B7-1 in human monocyte-derived antigen-presenting cells. Eur J Immunol 1997; 27: 2634–2642PubMedCrossRefGoogle Scholar
  142. 142.
    Piedrafita D., Xu D., Hunter D., et al. Protective immune responses induced by vaccination with an expression genomic library of Leishmania major. J Immunol 1999; 163: 1467–1472PubMedGoogle Scholar
  143. 143.
    Melby P.C., Ogden G.B., Flores H.A., et al. Identification of vaccine candidates for experimental visceral leishmaniasis by immunization with sequential fractions of a cDNA expression library. Infect Immun 2000; 68: 5595–5602PubMedCrossRefGoogle Scholar
  144. 144.
    Scott P., Pearce E., Natovitz P., et al. Vaccination against cutaneous leishmaniasis in a murine model; I, induction of protective immunity with a soluble extract of promastigotes. J Immunol 1987; 139: 221–227PubMedGoogle Scholar
  145. 145.
    Maxwell J.R., Weinberg A., Prell R.A., et al. Danger and OX40 receptor signaling synergize to enhance memory T cell survival by inhibiting peripheral deletion. J Immunol 2000; 164: 107–112PubMedGoogle Scholar
  146. 146.
    Klinman D.M., Yamshchikov G., Ishigatsubo Y. Contribution of CpG motifs to the immunogenicity of DNA vaccines. J Immunol 1997; 158: 3635–3639PubMedGoogle Scholar
  147. 147.
    Krieg A.M., Yi A.K., Schorr J., et al. The role of CpG dinucleotides in DNA vaccines. Trends Microbiol 1998; 6: 23–27PubMedCrossRefGoogle Scholar
  148. 148.
    Chu R.S., Targoni O.S., Krieg A.M., et al. CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity. J Exp Med 1997; 186: 1623–1631PubMedCrossRefGoogle Scholar
  149. 149.
    Jakob T., Walker P.S., Krieg A.M., et al. Activation of cutaneous dendritic cells by CpG-containing oligodeoxynucleotides: a role for dendritic cells in the augmentation of Th1 responses by immunostimulatory DNA. J Immunol 1998; 161: 3042–3049PubMedGoogle Scholar
  150. 150.
    Jakob T., Walker P.S., Krieg A.M., et al. Bacterial DNA and CpG-containing oligodeoxynucleotides activate cutaneous dendritic cells and induce IL-12 production: implications for the augmentation of Th1 responses. Int Arch Allergy Immunol 1999; 118: 457–461PubMedCrossRefGoogle Scholar
  151. 151.
    Walker P.S., Scharton-Kersten T., Krieg A.M., et al. Immunostimulatory oligodeoxynucleotides promote protective immunity and provide systemic therapy for leishmaniasis via IL-12- and IFN-gamma- dependent mechanisms. Proc Natl Acad Sci U S A 1999; 96: 6970–6975PubMedCrossRefGoogle Scholar
  152. 152.
    Stacey K.J., Blackwell J.M. Immunostimulatory DNA as an adjuvant in vaccination against Leishmania major. Infect Immun 1999; 67: 3719–3726PubMedGoogle Scholar

Copyright information

© Adis International Limited 2002

Authors and Affiliations

  1. 1.Department of Veterans Affairs Medical Center, Medical ServiceSouth Texas Veterans Health Care SystemSan AntonioUSA
  2. 2.Departments of Medicine and Microbiology, Division of Infectious DiseasesThe University of Texas Health Science CenterSan AntonioUSA

Personalised recommendations